Mahon Paul A exercised Options for 8,300 United Therapeutics shares at $146.03 each, then sold 8,300 shares across 11 transactions priced from $478.93 to $490.88. His directly held shares fell to 45,172 after the sales, while his derivative securities holdings stood at 55,840, giving investors updated ownership figures.
Key Highlights
- Mahon Paul A exercised options for 8,300 United Therapeutics shares at $146.03 per share on 3 September 2026.
- He sold 8,300 United Therapeutics shares across 11 transactions at prices ranging from $478.93 to $490.88 per share.
- Following the transactions, he owned 45,172 United Therapeutics shares and 55,840 derivative securities.
Mahon Paul A, executive vice president and general counsel of United Therapeutics (NASDAQ: UTHR) Corp, exercised options for 8,300 shares at $146.03 per share on 3 September 2026. He then sold the same number of United Therapeutics shares in 11 transactions, with sale prices ranging from $478.93 to $490.88 per share.
United Therapeutics Share Transactions The
option exercise left Mahon with 53,472 United Therapeutics shares before the subsequent sales. The transactions carried SEC code M for the exercise and SEC code S for the sales. After completing the sales, Mahon held 45,172 United Therapeutics shares. The exercise also involved 8,300 derivative securities. Mahon’s derivative securities holdings stood at 55,840 after that transaction.
Updated Direct
and Derivative Holdings The transactions changed the reported balance of Mahon’s United Therapeutics shares from 53,472 after the exercise to 45,172 after the sales. The sales were reported across 11 separate transactions. The filing reports separate ownership figures for United Therapeutics shares and derivative securities. Mahon held 55,840 derivative securities after exercising the options.
FAQs
Q: What did Mahon Paul A do with United Therapeutics shares?
A: Mahon Paul A exercised options for 8,300 United Therapeutics shares at $146.03 per share, then sold 8,300 shares across 11 transactions on 3 September 2026.
Q: How many United Therapeutics shares did Mahon Paul A own after the sale?
A: Mahon Paul A’s reported ownership was 45,172 United Therapeutics shares after the sales. His holdings immediately after the option exercise were 53,472 shares.
Q: What was the price range for Mahon Paul A’s share sales?
A: The 8,300 United Therapeutics shares were sold in transactions priced from $478.93 to $490.88 per share. The sales carried SEC transaction code S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.